Org Biomol Chem:科学家研发出一种能更有效抗击HIV的核苷修饰型新药!

2017-06-20 sunshine2015 来宝网

随着艾滋病毒/艾滋病疫情进入其第四个十年,每年都会带来有前途的研究新消息,以减轻祸患。纽约市科学院的科学家也加入新研究,以快速的方法抑制引起艾滋病的病毒的新分子。



研究人员制造对抗HIV的新分子】随着艾滋病毒/艾滋病疫情进入其第四个十年,每年都会带来有前途的研究新消息,以减轻祸患。纽约市科学院的科学家也加入新研究,以快速的方法抑制引起艾滋病的病毒的新分子。

化学与生物化学与化学系副主任Mahesh K. Lakshman以及学生Hari Akula领导了CCNY研究,该研究专注于核苷的修饰。这些都是所有生物体中的遗传建筑材料,因此它们作为抗病毒剂具有很大的潜力。

快速修饰天然核苷结构的能力是开发潜在药剂的核心。这可能产生多种化合物,然后可以对其进行测试,以了解对生物活性的结构影响。皇家化学学会研究员Lakshman说:“修饰嘧啶核苷,包括AZT(齐多夫定)——一种用于控制艾滋病毒感染的药物就是这种情况。

在这种情况下,Lakshman和Akula已经开发了一种简单而快速的制备新的嘧啶核苷类似物的方法,AZT属于AZT家族,用于修饰AZT本身。与他们在Rega医学研究所的合作者一起,他们已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。

他们的研究出现在皇家化学学会出版物“有机和生物分子化学”中。

据日内瓦的艾滋病方案说,截至2015年,自艾滋病开始以来,估计有三千五百万人因艾滋病相关疾病死亡。

然而,艾滋病毒在发展抗逆转录病毒疗法后不再被认为是死刑判决。因此,艾滋病规划署估计,世界各地有超过1800万人感染艾滋病毒。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917526, encodeId=2e07191e526f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 01:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300024, encodeId=84c613000249e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569290, encodeId=0d88156929045, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213094, encodeId=fe5b21309481, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jun 20 10:16:19 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213059, encodeId=bfe1213059b6, content=已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Jun 20 08:40:53 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2018-06-02 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917526, encodeId=2e07191e526f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 01:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300024, encodeId=84c613000249e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569290, encodeId=0d88156929045, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213094, encodeId=fe5b21309481, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jun 20 10:16:19 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213059, encodeId=bfe1213059b6, content=已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Jun 20 08:40:53 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-21 lqvr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917526, encodeId=2e07191e526f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 01:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300024, encodeId=84c613000249e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569290, encodeId=0d88156929045, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213094, encodeId=fe5b21309481, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jun 20 10:16:19 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213059, encodeId=bfe1213059b6, content=已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Jun 20 08:40:53 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-21 zhangyxzsh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917526, encodeId=2e07191e526f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 01:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300024, encodeId=84c613000249e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569290, encodeId=0d88156929045, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213094, encodeId=fe5b21309481, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jun 20 10:16:19 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213059, encodeId=bfe1213059b6, content=已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Jun 20 08:40:53 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 189****7206

    学习了谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917526, encodeId=2e07191e526f3, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jun 02 01:18:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300024, encodeId=84c613000249e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569290, encodeId=0d88156929045, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jun 21 23:18:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213094, encodeId=fe5b21309481, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Tue Jun 20 10:16:19 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213059, encodeId=bfe1213059b6, content=已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3wrgsNyr5lh6N2MY5xSnbvo4g5sRlc3MZoDdWpMeSdozUCPNhA96wndwQe3X5Z5oYMNxVUdOib63nw/0, createdBy=d8d11998754, createdName=Julie W, createdTime=Tue Jun 20 08:40:53 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 Julie W

    已经确定了几种新的化合物,对抗更强毒的HIV-1和较不常见和较少致病性的HIV-2活跃型。

    0

相关资讯

Hepatology:肝纤维化FIB-4分期可预测HIV感染与非感染者心力衰竭风险

肝纤维化流行率高,尤其在人类免疫缺陷病毒(HIV)感染患者中。相比未感染者,HIV感染者充血性心力衰竭风险增加。肝纤维化分期是否与充血性心力衰竭事件相关,是否HIV或者丙型肝炎病毒(HCV)感染会改变此相关性,目前仍不清楚。近期美国学者于著名肝脏病学杂志Hepatology发表文章以评价:(1)肝纤维化分期是否与充血性心力衰竭独立相关;(2)肝纤维化分期与充血性心力衰竭的相关性是否会受HIV/HC

2017年5月CRISPR/Cas亮点盘点

2017年5月30日/生物谷BIOON/---基因组编辑技术CRISPR/Cas9被《科学》杂志列为2013年年度十大科技进展之一,受到人们的高度重视。CRISPR是规律间隔性成簇短回文重复序列的简称,Cas是CRISPR相关蛋白的简称。CRISPR/Cas最初是在细菌体内发现的,是细菌用来识别和摧毁抗噬菌体和其他病原体入侵的防御系统。 即将过去的5月份,有哪些重大的CRISPR/

Nature:美学者发现抗体治疗让猕猴持久控制类HIV病毒

美国洛克菲勒大学Michel C. Nussenzweig研究员和美国国立卫生研究院Malcolm A. Martin研究员合作的一篇研究论文。研究人员针对猕猴的研究表明:猕猴感染类HIV(艾滋病病毒)后,立即用两种HIV抗体进行治疗,可使其免疫系统有效地控制病毒,防止它们卷土重来。

J NAT PROD:爵床属植物化合物消灭HIV效果惊人!

近日,发表于《自然》杂志上的一篇文章表示,遍布东南亚的一种植物提取物可以更加有效的对抗HIV病毒,先前,这种植物提取物常用来治疗关节炎和风湿病。这种化学物质叫做,patentiflorin,来自于柳树叶爵床属中,它对抗HIV病毒非常有效。

NEJM:HIV黄色霉菌感染治疗——两性霉素vs伊曲康唑

HIV黄色霉菌感染患者,两性霉素在6个月死亡率、临床应答和抗菌活性方面优于伊曲康唑。

Hepatology:HIV合并HCV,标准治疗效果如何?

根据6月13日在肝病学杂志上发表的一项研究的结果显示,对于具有艾滋病毒合并感染丙型肝炎病毒(HCV)的城市诊所的患者来说,丙型肝炎治疗对标准化护士/药剂师的支持治疗是有效的。